



The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit

**Thesis submitted for the fulfillment of master's degree in Pharmaceutical Sciences
(Clinical Pharmacy)**

Submitted By

Eman Ahmed El-Said Ahmed Casper

Bachelor of Pharmaceutical Sciences

Demonstrator of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Under supervision of:

Prof. Dr. Manal Hamed El Hamamsy

Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Prof. Dr. Mohamed Ayman Saleh

Professor of Cardiology

Cardiology department

Faculty of Medicine

Ain shams University

Dr. Lamia Mohamed El Wakeel

Assistant Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

2019

The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit

**Thesis submitted for the fulfillment of master's degree in Pharmaceutical Sciences
(Clinical Pharmacy)**

Submitted By

Eman Ahmed El-Said Ahmed Casper

Bachelor of Pharmaceutical Sciences

Demonstrator of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Under supervision of:

Prof. Dr. Manal Hamed El Hamamsy

Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Prof. Dr. Mohamed Ayman Saleh

Professor of Cardiology

Cardiology department

Faculty of Medicine

Ain shams University

Dr. Lamia Mohamed El Wakeel

Assistant Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

2019



تأثير ممارسة الرعاية الصيدلانية على المرضى في وحدة إعادة تأهيل القلب

رسالة مقدمة للحصول على درجة الماجستير في العلوم الصيدلانية (صيدلة اكلينيكية)

مقدمة من

الصيدلانية / ايمان احمد السيد احمد كسبر

معيده بقسم الصيدلة الاكلينيكية
كلية الصيدلة - جامعة عين شمس

تحت إشراف

أ.د. محمد ايمن صالح

أستاذ القلب و الأوعية الدموية

كلية الطب

جامعة عين شمس

اد. منال حامد الحماصى

استاذ الصيدلة الاكلينيكية

كلية الصيدله

جامعة عين شمس

ا.م. د. لمياء محمد الوكيل

أستاذ مساعد الصيدلة الاكلينيكيه

كلية الصيدله - جامعة عين شمس

كلية الصيدلة

جامعة عين شمس

٢٠١٩

تأثير ممارسة الرعاية الصيدلانية على المرضى في وحدة إعادة تأهيل القلب

رسالة مقدمة للحصول على درجة الماجستير في العلوم الصيدلانية (صيدلة اكلينيكية)

مقدمة من

الصيدلانية / ايمان احمد السيد احمد كسبر

معيده بقسم الصيدلة الاكلينيكية
كلية الصيدلة - جامعة عين شمس

تحت إشراف

ا.د . منال حامد الحمامصي

استاذ الصيدلة الاكلينيكية
كلية الصيدله
جامعة عين شمس

أ.د. محمد ايمن صالح

أستاذ القلب و الأوعية الدموية
كلية الطب
جامعة عين شمس

ا.م. د . لمياء محمد الوكيل

أستاذ مساعد الصيدلة الاكلينيكيه
كلية الصيدله - جامعة عين شمس
كلية الصيدلة
جامعة عين شمس

٢٠١٩

Acknowledgements

I am deeply thankful to "Allah" by the grace of whom, this work was possible.

*I would like to express my deep appreciation to **Dr. Manal Hamed El Hamamsy**, Professor of Clinical Pharmacy – Faculty of Pharmacy - Ain Shams University, for her sincere help, valuable guidance and continuous support in completing this work.*

*I am very grateful to **Dr. Mohamed Ayman Saleh**, Professor of Cardiology – Faculty of Medicine – Ain Shams University, for his great assistance, precious advice and valuable guidance in completing this work.*

*I extend my gratitude to **Dr. Lamia Mohamed El Wakeel** for her loving support, valuable efforts, precious time and mostly for giving me the hope and the space to be.*

I would like to thank all members of the Clinical Pharmacy Department, Faculty of Pharmacy- Ain Shams University, for their support and continuous encouragement.

Last but not the least, I would like to dedicate this work and express my deep appreciation to my parents, family, dear husband and friends, to whom I am greatly indebted for their love and spiritual support throughout my life.

Table of Contents

List of Tables	iii
List of Figures	v
List of abbreviations	viii
ABSTRACT	xiii
REVIEW OF LITERATURE	1
1. Acute Coronary Syndromes	1
<i>1.A. Epidemiology and Definition</i>	1
<i>1.B. Risk Factors</i>	2
<i>1.C. Types of acute coronary syndrome (ACS)</i>	3
<i>1.D. Etiology</i>	4
<i>1.E. Pathogenesis of acute coronary syndrome (ACS)</i>	4
<i>1.F. Diagnosis of acute coronary syndrome (ACS)</i>	7
<i>1.G. Prognosis of acute coronary syndrome (ACS)</i>	15
<i>1.H. Primary prevention</i>	15
2.Cardiac Rehabilitation (CR)	22
3.Role of the clinical pharmacist in the cardiac rehabilitation unit	28
AIM OF THE WORK	38
PATIENTS AND METHODS	39
DISCUSSION	88
CONCLUSION	102
RECOMMENDATIONS	103
SUMMARY	104
REFERENCES	139
الملخص العربي	149

List of Tables

TABLE 1: RISK FACTORS ASSOCIATED WITH CORONARY HEART DISEASE	3
TABLE 2 : DIFFERENTIAL DIAGNOSES OF ACUTE CORONARY SYNDROMES IN THE SETTING OF ACUTE CHEST PAIN.....	8
TABLE 3: THE CANADIAN CARDIOVASCULAR SOCIETY (CCS) FUNCTIONAL CLASSIFICATION OF ANGINA.....	10
TABLE 4: REASONS FOR MEDICATION NONADHERENCE.....	35
TABLE 5: PATIENTS' DEMOGRAPHICS IN BOTH GROUPS.....	50
TABLE 6: CLINICAL EVALUATION FOR BOTH GROUPS AT BASELINE.....	51
TABLE 7: RISK FACTORS FOR CARDIOVASCULAR DISEASE IN BOTH GROUPS.....	52
TABLE 8: MEDICATIONS ADMINISTERED BY BOTH GROUPS AT BASELINE	53
TABLE 9: LIPID PROFILE FOR BOTH GROUPS AT BASELINE.....	55
TABLE 10: BASELINE LABORATORY PARAMETERS FOR BOTH GROUPS...	56
TABLE 11: SHORT FORM 36 HEALTH SURVEY QUESTIONNAIRE (SF-36) SCORES IN CONTROL AND INTERVENTION GROUPS AT BASELINE.....	57
TABLE 12: CADE, MMAS, MNA QUESTIONNAIRES SCORES IN BOTH GROUPS AT BASELINE.....	59
TABLE 13: PREVALENCE OF CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE (CADEQ) DIFFERENT CATEGORIES AMONG INTERVENTION AND CONTROL GROUPS AT BASELINE.....	59
TABLE 14: PREVALENCE OF LOW, MEDIUM, AND HIGH MORISKY MEDICATION ADHERENCE SCALE (MMAS-8) SCORES AMONG INTERVENTION AND CONTROL GROUPS AT BASELINE.....	60
TABLE 15: FAGERSTORM QUESTIONNAIRE SCORES IN CONTROL AND INTERVENTION GROUPS AT BASELINE.....	60
TABLE 16: BASELINE ECHOCARDIOGRAPHIC PARAMETERS FOR BOTH GROUPS.....	62

TABLE 17: BASELINE ECHOCARDIOGRAPHIC PARAMETERS FOR BOTH GROUPS	63
TABLE 18: PERCENT CHANGE OF SBP, DBP AND BMI IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	67
TABLE 19: MEDICATIONS ADMINISTERED BY BOTH INTERVENTION AND CONTROL GROUPS AFTER THREE MONTHS	68
TABLE 20: PERCENT CHANGE OF FBS AND LIPID PROFILE LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.	72
TABLE 21: PERCENT CHANGE OF LAB PARAMETERS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	74
TABLE 22: FAGERSTORM QUESTIONNAIRE SCORES IN CONTROL AND INTERVENTION GROUPS AFTER 3 MONTHS	77
TABLE 23: PERCENT CHANGE OF CADE, MMAS AND MNA QUESTIONNAIRES SCORES IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	77
TABLE 24: PREVALENCE OF CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE (CADEQ) DIFFERENT CATEGORIES AMONG INTERVENTION AND CONTROL GROUPS AFTER 3MONTHS	78
TABLE 25: PREVALENCE OF LOW, MEDIUM, AND HIGH MORISKY MEDICATION ADHERENCE SCALE (MMAS-8) SCORES AMONG INTERVENTION AND CONTROL GROUPS AFTER 3 MONTHS	78
TABLE 26: SHORT FORM 36 HEALTH SURVEY QUESTIONNAIRE (SF-36) SCORES IN CONTROL AND INTERVENTION GROUPS AT BASELINE AND AFTER THREE MONTHS	79
TABLE 27: PERCENT CHANGE OF ECHOCARDIOGRAPHIC PARAMETERS FOR BOTH GROUPS AT THE END OF THE STUDY.....	83
TABLE 28: MEDIAN NUMBER OF DRUG-RELATED PROBLEMS IN THE INTERVENTION AND CONTROL GROUPS AFTER THREE MONTHS.....	84

List of Figures

FIGURE 1: THE SPECTRUM OF ACUTE CORONARY SYNDROMES.....	4
FIGURE 2:PROGRESSION OF AN ATHEROSCLEROTIC LESION.....	6
FIGURE 3: MACROPHAGES IN ADVANCED ATHEROSCLEROTIC LESIONS...	7
FIGURE 4: INITIAL DIAGNOSIS OF ACUTE CORONARY SYNDROMES USING ELECTROCARDIOGRAM.....	12
FIGURE 5: INITIAL ASSESSMENT OF PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROMES.....	13
FIGURE 6: TIMING OF RELEASE OF VARIOUS BIOMARKERS AFTER ACUTE MYOCARDIAL INFARCTION (AMI).	14
FIGURE 7: SUMMARY ALGORITHM FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME (ACS).	17
FIGURE 8: THERAPEUTIC APPROACH TO PREVENTION OF ADVERSE OUTCOMES ACCORDING TO VASCULAR PROTECTION, CARDIAC PROTECTION, AND RISK FACTOR MANAGEMENT.....	18
FIGURE 9:THE HEALTH CONSEQUENCES CAUSALLY LINKED TO SMOKING	25
FIGURE 10: ROLE OF THE CLINICAL PHARMACIST IN CVD SECONDARY PREVENTION.....	29
FIGURE 11: STEPS OF PHARMACEUTICAL CARE PLAN	32
FIGURE 12: STUDY DESIGN FLOW DIAGRAM.....	49
FIGURE 13: PIE CHART SHOWING PERCENTAGE OF CARDIOVASCULAR DRUGS USED IN THE CONTROL AND INTERVENTION GROUPS AT BASELINE.....	54
FIGURE 14: MEDIAN SF-36 QUALITY OF LIFE DOMAIN SCORES FOR INTERVENTION AND CONTROL GROUPS AT BASELINE	58
FIGURE 15: PIE CHART SHOWING THE PREVALENCE OF CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE (CADEQ) DIFFERENT CATEGORIES AMONG INTERVENTION AND CONTROL GROUPS AT BASELINE.....	61
FIGURE 16: PIE CHART SHOWING THE PREVALENCE OF LOW, MEDIUM, AND HIGH MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)	

SCORES AMONG INTERVENTION AND CONTROL GROUPS AT BASELINE.....	61
FIGURE 17: PIE CHART SHOWING THE PREVALENCE OF LOW, LOW- MODERATE, MODERATE, AND HIGH CLASSES OF FAGERSTORM QUESTIONNAIRE AMONG INTERVENTION AND CONTROL GROUPS AT BASELINE.....	62
FIGURE 18:PIE CHART SHOWING BASELINE DRUG-RELATED PROBLEMS IN THE CONTROL AND INTERVENTION GROUPS AT BASELINE.....	64
FIGURE 19: DRUG-RELATED PROBLEMS IN THE CONTROL AND INTERVENTION GROUPS AT BASELINE.....	65
FIGURE 20: BOXPLOT OF PERCENT CHANGE OF BMI IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	65
FIGURE 21: BOXPLOT OF PERCENT CHANGE OF SBP LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	66
FIGURE 22: BOXPLOT OF PERCENT CHANGE OF DBP IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	66
FIGURE 23: BOXPLOT OF PERCENT CHANGE OF HEART RATE IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	67
FIGURE 24: PIE CHART SHOWING PERCENTAGE OF CARDIOVASCULAR DRUGS USED IN THE CONTROL AND INTERVENTION GROUPS AFTER 3 MONTHS	69
FIGURE 25: BOXPLOT OF PERCENT CHANGE OF FASTING BLOOD SUGAR LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	70
FIGURE 26: BOXPLOT OF PERCENT CHANGE OF TOTAL CHOLESTEROL LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	70
FIGURE 27: BOXPLOT OF PERCENT CHANGE OF LDL LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	71
FIGURE 28: BOXPLOT OF PERCENT CHANGE OF TRIGLYCERIDES LEVELS IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	72
FIGURE 29: FAGERSTORM SCORES FOR INTERVENTION AND CONTROL GROUPS AT THE END OF THE STUDY.....	75

FIGURE 30: PIE CHART SHOWING THE PREVALENCE OF CORONARY ARTERY DISEASE EDUCATION QUESTIONNAIRE (CADEQ) DIFFERENT CATEGORIES AMONG INTERVENTION AND CONTROL GROUPS AFTER 3MONTHS.....	76
FIGURE 31: PIE CHART SHOWING THE PREVALENCE OF LOW, MEDIUM, AND HIGH MORISKY MEDICATION ADHERENCE SCALE (MMAS-8) SCORES AMONG INTERVENTION AND CONTROL GROUPS AFTER 3 MONTHS	76
FIGURE 32: MEDIAN SF-36 QUALITY OF LIFE DOMAIN SCORES FOR INTERVENTION AND CONTROL GROUPS AT THE END OF THE STUDY	80
FIGURE 33: BOXPLOT OF PERCENT CHANGE OF LVESV IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	81
FIGURE 34: BOXPLOT OF PERCENT CHANGE OF LVEDV IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	81
FIGURE 35: BOXPLOT OF PERCENT CHANGE OF EF% IN CONTROL AND INTERVENTION AT THE END OF THE STUDY	82
FIGURE 36: BOXPLOT OF PERCENT CHANGE OF E/E' RATIO IN CONTROL AND INTERVENTION AT THE END OF THE STUDY.....	82
FIGURE 37: DRUG-RELATED PROBLEMS IN THE CONTROL AND INTERVENTION GROUPS AFTER 3 MONTHS.....	85
FIGURE 38: DRUG-RELATED PROBLEMS IN THE INTERVENTION GROUP AT BASELINE AND AFTER 3 MONTHS	85
FIGURE 39: PIE CHART SHOWING DRUG-RELATED PROBLEMS IN THE CONTROL GROUP AFTER 3 MONTHS.....	86
FIGURE 40: PIE CHART SHOWING ACTIONS TAKEN BY THE CLINICAL PHARMACIST TO HANDLE DRUG RELATED PROBLEMS IN THE INTERVENTION GROUP.....	87

List of abbreviations

ACC	American College of Cardiology
ACEI	Angiotensin converting enzyme inhibitor
ACS	Acute coronary syndrome
ACT	Activated clotting time
ADE	Adverse drug event
ADP	Adenosine diphosphate
ADR	Adverse drug reaction
AHA	American Heart Association
AMI	Acute myocardial infarction
aPTT	Activated partial thromboplastin time
ARB	Angiotensin receptor blocker
ASA	Aspirin
AST	Aspartate aminotransferase
AT	Antithrombin
ATP	Adenosine Triphosphate
ALT	Alanine aminotransferase
BMI	Body mass index
BMS	Bare metal stent
BP	Blood pressure
CABG	Coronary artery bypass graft
CAD	Coronary artery disease
CADE-Q	Coronary artery disease education questionnaire

CCS	Canadian Cardiovascular Society
CCB	Calcium channel blocker
CE	Cholesteryl Ester
CG	Control Group
CHD	Coronary heart disease
CKD	Chronic kidney disease
CK-MB	Creatinine kinase-Muscle/Brain
CMD	Coronary microvascular dysfunction
CMR	Cardiac magnetic resonance imaging
COX-1	Cyclooxygenase-1
CR	Cardiac rehabilitation
CrCl	Creatinine clearance
CT	Computed tomography
CTn	Cardiac troponin
CV	Cardiovascular
CVD	Cardiovascular disease
CYP	Cytochrome
DAPT	Dual Antiplatelet Therapy
DBP	Diastolic Blood Pressure
DES	Drug Eluting Stent
DM	Diabetes Mellitus
DRP	Drug Related Problems
ECG	Electrocardiograph

EDV	End Diastolic Volume
ESC	European Society of Cardiology
ESV	End Systolic Volume
EV	Energy Vitality
FBG	Fasting Blood Glucose
FDA	Food and Drug Administration
FMC	First Medical Contact
GH	General Health Perception
GP	General Practitioner
GPI	Glycoprotein Inhibitor
GRACE	Global Registry of Acute Coronary Events
HB	Hemoglobin
HDL	High Density Lipoprotein
HF	Heart Failure
HIT	Heparin Induced Thrombocytopenia
HR	Heart Rate
IG	Intervention Group
IHD	Ischemic Heart Disease
IHI	Institute of Healthcare Improvement
Il-1b	Interleukine 1b
INR	International Normalized Ratio
IQR	Interquartile Range
IU	International Unit

IV	Intravenous
LAD	Left Anterior Descending
LBBB	Left Bundle Branch Block
LDL	Low Density Lipoprotein
LMWH	Low Molecular Weight Heparin
LV	Left Ventricle
LVEF	Left Ventricle Ejection Fraction
LVH	Left Ventricle Hypertrophy
MCP-1	Macrophage Chemoattractant Protein-1
MH	Mental Health
MI	Myocardial Infarction
MMAS-8	Morisky Medication Adherence Scale-8
MNA	Mini Nutritional Assessment
NonSTEACS	Non ST segment Elevation Acute Coronary Syndrome
NonSTEMI	Non ST segment Elevation Myocardial Infarction
NTG	Nitroglycerin
OTC	Over The Counter
PAD	Peripheral Artery Disease
PCI	Percutaneous Coronary Intervention
PE	Pulmonary Embolism
PF	Physical functioning
PPI	Proton Pump Inhibitor
PTCA	Percutaneous Transluminal Coronary Angioplasty